Why the study?
Anticoagulation management in elderly AF patients is complicated by comorbidities, altered organ function, frailty, and a lack of RCTs specifically for this group, leading to OAC underuse.
Do NOACs improve stroke prevention and safety in elderly patients with atrial fibrillation compared to warfarin?
Do NOACs improve stroke prevention and safety in elderly patients with atrial fibrillation compared to warfarin?
NOACs are generally favored over warfarin for stroke prevention in elderly AF patients, though optimal choice and dosing require careful consideration of renal function and other risk factors.
Supports OAC use in elderly AF despite frailty; confirms NOAC preference over warfarin from RCT subanalyses.
Aging is an important risk factor for adverse events in elderly patients with atrial fibrillation (AF) and complicates the management of anticoagulation. Underuse of oral anticoagulants (OACs) is common in elderly patients because of comorbidities, the altered physiological function of multiple organs, frailty, risk of falls, and the lack of randomized controlled trials (RCTs) specifically for elderly patients. Nevertheless, current data still support OACs use for reducing ischemic stroke with positive net clinical benefits. Sub-analyses of RCTs and real-world cohort studies showed that non-vitamin K antagonist OACs (NOACs) would be more favorable choices compared to warfarin for stroke prevention in the elderly. This review will discuss important data on stroke prevention and the use of NOACs in elderly AF patients.
No takes yet. Share an insight, caveat, or question.
A 2022 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: